Terumo BCT, Inc. and Fresenius SE & Co. KGAA are Leading Players in the Leukapheresis Market
The global leukapheresis products market is projected to reach USD 100 million by 2028 from USD 70 million in 2023, at a CAGR of 8.3%. The global leukopaks market is projected to reach USD 1020 million by 2028 from USD 200 million in 2023, at a CAGR of 38.1%.
The leukepheresis and leukopaks market is growing due to the increasing incidence and prevalence of leukemia, the growing demand for leukopaks in research applications, and the rising number of CAR T-cell therapy clinical trials. Leukapheresis is a medical procedure that removes white blood cells from the blood. Leukopaks are blood products that contain a high concentration of white blood cells.
To know about the assumptions considered for the study download the pdf brochure
The incidence and prevalence of leukemia is increasing worldwide due to factors such as environmental pollution, exposure to radiation, and unhealthy lifestyle habits. This is driving the demand for leukapheresis and leukopaks, which are used to treat leukemia. Leukopaks are also used in research applications, such as the development of new cancer treatments. The demand for leukopaks is growing due to the increasing number of research studies being conducted on cancer.
The prominent players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany). Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US). The players are constantly innovating and developing new products to meet the needs of patients and healthcare providers. The players are acquiring smaller companies to gain access to new technologies and markets. For example, Terumo BCT, Inc. acquired BioLife Solutions in 2021.
Terumo BCT, Inc.
Terumo BCT, Inc. is a global medical device company that develops, manufactures, and markets a wide range of products for blood collection, processing, and transfusion. The company's leukapheresis products are used to collect white blood cells from the blood for a variety of medical procedures, such as treating leukemia and other blood disorders. Terumo BCT's leukapheresis products are used in hospitals, blood banks, and research laboratories around the world. In 2021, Terumo BCT acquired BioLife Solutions, a leading provider of plasma collection and cryopreservation products. This acquisition expands Terumo BCT's product portfolio and strengthens its position in the blood and plasma products market. Terumo BCT is committed to providing innovative products and services that help patients and healthcare providers. The company is a leader in the leukapheresis market and is committed to continuing to develop new products and technologies that improve the lives of patients.
Fresenius SE & Co. KGAA
Fresenius is a multinational healthcare company that develops, manufactures, and distributes products and services for patients with kidney disease, other chronic diseases, and those undergoing surgery. The company offers a range of products and services for leukapheresis, including apheresis machines, disposables, and services. Fresenius's leukapheresis products and services are used in hospitals, blood banks, and research laboratories around the world. In 2021, Fresenius launched the Prismaflex Apheresis System, a new apheresis machine that is designed to be more user-friendly and efficient than previous models.
Charles River Laboratories International, Inc.
Charles River Laboratories is a global life sciences company that provides drug discovery, development, and manufacturing services. The company's leukopaks are blood products that contain a high concentration of white blood cells. They are used in research applications, such as the development of new cancer treatments. The company focuses on inorganic growth strategies including acquisitions to strengthen its position in the market. For instance, in March 2021, the company acquired The contract research organization Retrogenix Limited to increase the company’s scientific expertise with additional large molecule and cell therapy discovery expertise.
Related Reports:
Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
